Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Piramal Healthcare Buys Rights To Sell Germany’s PlasmaSelect

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - India's Piramal Healthcare said it has bought the global rights to market blood plasma products of Germany-based PlasmaSelect for an undisclosed amount in a deal that excludes the company's manufacturing unit at Marburg, Germany

You may also be interested in...



Analysts Rate Piramal Healthcare Best Play On Innovator CRAMS

MUMBAI - Piramal Healthcare was rated by Citigroup Analysts as India's best play on innovator CRAMS, following its FY09 earnings call July 24

Analysts Rate Piramal Healthcare Best Play On Innovator CRAMS

MUMBAI - Piramal Healthcare was rated by Citigroup Analysts as India's best play on innovator CRAMS, following its FY09 earnings call July 24

PharmAsia News India Pharma Roundup: Lupin, Strides Arcolab, GSK India, Nicholas Piramal, Jubilant

NEW DELHI - India's fifth largest generic drug firm Lupin wants to buy other drug formulation companies in the U.S., Latin America, Southeast Asia and the Middle East this year to expand its presence overseas its chairman said after announcing a sharp, but expected, drop in earnings for the fourth quarter ended March 31

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel